Generate Biomedicines (NASDAQ:GENB) Sets New 12-Month High – Here’s Why

Generate Biomedicines Inc (NASDAQ:GENB)’s share price hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $16.79 and last traded at $16.2890, with a volume of 484229 shares. The stock had previously closed at $15.43.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on GENB. Wall Street Zen cut shares of Generate Biomedicines from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Zacks Research raised Generate Biomedicines to a “hold” rating in a research report on Wednesday, March 25th. The Goldman Sachs Group initiated coverage on Generate Biomedicines in a research report on Tuesday, March 24th. They set a “buy” rating and a $26.00 target price on the stock. Piper Sandler started coverage on Generate Biomedicines in a report on Tuesday, March 24th. They issued an “overweight” rating and a $24.00 price target for the company. Finally, HC Wainwright increased their price target on shares of Generate Biomedicines from $16.00 to $25.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Six equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, Generate Biomedicines has an average rating of “Moderate Buy” and an average price target of $25.40.

Generate Biomedicines Trading Up 5.2%

The stock’s 50 day simple moving average is $13.54.

Generate Biomedicines (NASDAQ:GENB) last posted its earnings results on Thursday, May 7th. The company reported ($1.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.59).

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.